The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term moderate-to-severe pain in adults. It’s the first of a new class of analgesics to be approved in over 20 years,

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.  “Today’s approval is

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The FDA approves Journavx, the first new non-opioid pain medication in over 20 years, offering a safer alternative for managing acute pain.

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.

A team of researchers at the University of the Pacific has developed an injectable version of Narcan that releases the opioid-reversal drug over a week-long period.